Objective To develop evidence-based recommendations for the non-pharmacological
management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Methods …

SLE is a heterogeneous, multi-organ autoimmune disease with a wide range of clinical and
laboratory abnormalities. The hallmark of lupus is the generation of autoantibodies directed …

The latest report that belimumab, a human monoclonal antibody targeting BAFF (B-cell
activating factor, also known as TNF ligand superfamily member 13B or BLyS), was not …

Background: Treat-to-target in systemic lupus erythematosus (SLE) has been proposed for 7
years and several recommendations were developed [1]. In these recommendations …

Over the past decades, the concept of 'remission'has emerged as a moniker for the disease
state one would ideally like to achieve when a 'cure'—the ultimate goal of medical …

Systemic lupus erythematosus (SLE) imposes a great burden on the lives of patients.
Patients' and physicians' concerns about the disease diverge considerably. Physicians focus …

Objective To systematically develop a quality indicator (QI) set for systemic lupus
erythematosus (SLE). Methods We used a validated process that combined available …

Background Treat-to-target (T2T) is a generally accepted treatment concept in rheumatology
care. It is assumed that T2T could significantly improve systemic lupus erythematosus (SLE) …

Systemic lupus erythematosus (SLE) is classically regarded as the landmark of systemic
autoimmune diseases, characterised by protean, multi-systemic manifestations and a highly …

In the parable of the blind men who encounter an elephant for the first time, each man
touches a different body part of the animal (eg, tusk, leg, ear) and describes the creature …